Immunome Inc (NASDAQ:IMNM) price on Thursday, January 16, fall -2.47% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.86.
A look at the stock’s price movement, the close in the last trading session was $10.11, moving within a range at $9.6028 and $11.06. Turning to its 52-week performance, $30.96 and $8.97 were the 52-week high and 52-week low respectively. Overall, IMNM moved -21.62% over the past month.
Immunome Inc’s market cap currently stands at around $615.43 million, with investors looking forward to this quarter’s earnings report slated for in February.
The average forecast suggests down to a -17.51% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 9.41M, representing a -32.90% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IMNM is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend IMNM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IMNM’s current price about -7.90% and -15.31% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 38.75, while 7-day volatility ratio is 9.49% and 6.87% in the 30-day chart. Further, Immunome Inc (IMNM) has a beta value of 1.91, and an average true range (ATR) of 0.82. Analysts have given the company’s stock an average 52-week price target of $23, forecast between a low of $23 and high of $23. Looking at the price targets, the low is -133.27% off current price level while to achieve the yearly target high, price needs to move -133.27%. Nonetheless, investors will most likely welcome a -133.27% jump to $23 which is the analysts’ median price.
If we refocus on Immunome Inc (NASDAQ:IMNM), historical trading data shows that trading volumes averaged 0.67 over the past 10 days and 795.10K over the past 3 months. The company’s latest data on shares outstanding shows there are 60.42 million shares.
The 17.80% of Immunome Inc’s shares are in the hands of company insiders while institutional holders own 81.92% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.87 million on 2024-12-31, giving us a short ratio of 11.4. The data shows that as of 2024-12-31 short interest in Immunome Inc (IMNM) stood at 1670.0001 of shares outstanding, with shares short rising to 9.79 million registered in 2024-11-29. Current price change has pushed the stock -7.16% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IMNM stock continues to rise going into the next quarter.
